Cantor Fitzgerald began coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research report sent to investors on Friday. The firm issued a buy rating and a $150.00 price target on the stock.

A number of other analysts have also weighed in on NBIX. BidaskClub upgraded Neurocrine Biosciences from a buy rating to a strong-buy rating in a report on Thursday, June 21st. Oppenheimer set a $140.00 target price on Neurocrine Biosciences and gave the stock a buy rating in a report on Wednesday, September 12th. Needham & Company LLC set a $125.00 target price on Neurocrine Biosciences and gave the stock a buy rating in a report on Wednesday, August 1st. Stifel Nicolaus initiated coverage on Neurocrine Biosciences in a report on Tuesday, August 7th. They set a buy rating and a $137.00 target price for the company. Finally, HC Wainwright reiterated a buy rating and set a $162.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, August 1st. One research analyst has rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $121.83.

Neurocrine Biosciences stock opened at $118.48 on Friday. The company has a quick ratio of 9.19, a current ratio of 9.19 and a debt-to-equity ratio of 1.00. The firm has a market cap of $11.01 billion, a price-to-earnings ratio of -73.14, a P/E/G ratio of 38.39 and a beta of 0.42. Neurocrine Biosciences has a twelve month low of $55.95 and a twelve month high of $126.98.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, July 31st. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. The company had revenue of $96.90 million during the quarter, compared to analyst estimates of $84.11 million. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. Neurocrine Biosciences’s revenue was up 1428.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.68) earnings per share. analysts anticipate that Neurocrine Biosciences will post 0.15 earnings per share for the current fiscal year.

In related news, insider Dimitri E. Grigoriadis sold 23,022 shares of the company’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $110.00, for a total value of $2,532,420.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Dimitri E. Grigoriadis sold 23,000 shares of the company’s stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $105.00, for a total value of $2,415,000.00. Following the completion of the transaction, the insider now directly owns 105,942 shares in the company, valued at $11,123,910. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NBIX. Meeder Asset Management Inc. increased its position in shares of Neurocrine Biosciences by 643.7% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock valued at $110,000 after acquiring an additional 972 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Neurocrine Biosciences by 103.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,016 shares of the company’s stock valued at $167,000 after acquiring an additional 1,025 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Neurocrine Biosciences in the 1st quarter valued at $202,000. Commonwealth Equity Services LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at $203,000. Finally, NumerixS Investment Technologies Inc increased its position in shares of Neurocrine Biosciences by 90.9% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,100 shares of the company’s stock valued at $204,000 after acquiring an additional 1,000 shares during the period.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C.

Further Reading: Marijuana Stocks Future Looks Bright

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.